{"denoms":[{"counts":[{"groupId":"BG000","value":"202"},{"groupId":"BG001","value":"207"},{"groupId":"BG002","value":"201"},{"groupId":"BG003","value":"610"}],"units":"Participants"}],"groups":[{"description":"Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days.","id":"BG000","title":"Degarelix 240/160 mg"},{"description":"Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days.","id":"BG001","title":"Degarelix 240/80 mg"},{"description":"Lupron Depot 7.5 mg IM (in the muscle) every 28 days starting at day 0.","id":"BG002","title":"Leuprolide 7.5 mg"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"43"},{"groupId":"BG002","value":"38"},{"groupId":"BG003","value":"118"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"165"},{"groupId":"BG001","value":"164"},{"groupId":"BG002","value":"163"},{"groupId":"BG003","value":"492"}],"title":">=65 years"}]}],"description":"Intent-to-treat (ITT) population.","paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"50","spread":"8.47","upperLimit":"88","value":"72"},{"groupId":"BG001","lowerLimit":"51","spread":"8.12","upperLimit":"89","value":"72"},{"groupId":"BG002","lowerLimit":"52","spread":"8.77","upperLimit":"98","value":"74"},{"groupId":"BG003","lowerLimit":"50","spread":"8.45","upperLimit":"98","value":"73"}]}]}],"description":"ITT population.","dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"202"},{"groupId":"BG001","value":"207"},{"groupId":"BG002","value":"201"},{"groupId":"BG003","value":"610"}],"title":"Male"}]}],"description":"ITT population.","paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"19"},{"groupId":"BG003","value":"59"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"38"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"168"},{"groupId":"BG001","value":"171"},{"groupId":"BG002","value":"172"},{"groupId":"BG003","value":"511"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"Unknown or Not Reported"}]}],"description":"ITT population","paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"84"},{"groupId":"BG001","value":"87"},{"groupId":"BG002","value":"86"},{"groupId":"BG003","value":"257"}]}],"title":"North America"},{"categories":[{"measurements":[{"groupId":"BG000","value":"118"},{"groupId":"BG001","value":"120"},{"groupId":"BG002","value":"115"},{"groupId":"BG003","value":"353"}]}],"title":"Europe"}],"description":"ITT population","paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"78"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"178"},{"groupId":"BG001","value":"177"},{"groupId":"BG002","value":"177"},{"groupId":"BG003","value":"532"}]}],"title":"No"}],"description":"ITT population. Curative intent refers to radical prostatectomy or radiotherapy.","paramType":"NUMBER","title":"Curative Intent","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"65"}]}],"title":"2-4"},{"categories":[{"measurements":[{"groupId":"BG000","value":"67"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"63"},{"groupId":"BG003","value":"198"}]}],"title":"5-6"},{"categories":[{"measurements":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"63"},{"groupId":"BG002","value":"62"},{"groupId":"BG003","value":"181"}]}],"title":"7"},{"categories":[{"measurements":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"51"},{"groupId":"BG003","value":"163"}]}],"title":"8-10"}],"description":"ITT population. The Gleason score is a system of grading the aggressiveness of the prostate cancer and how fast it is likely to grow and spread. Scale is 2-10, with low numbers being the least aggressive and 10 being the most aggressive. Gleason scores were unavailable for 3 patients.","paramType":"NUMBER","title":"Gleason Score","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"59"},{"groupId":"BG001","value":"69"},{"groupId":"BG002","value":"63"},{"groupId":"BG003","value":"191"}]}],"title":"Localized"},{"categories":[{"measurements":[{"groupId":"BG000","value":"62"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"52"},{"groupId":"BG003","value":"178"}]}],"title":"Locally advanced"},{"categories":[{"measurements":[{"groupId":"BG000","value":"41"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"47"},{"groupId":"BG003","value":"125"}]}],"title":"Metastatic"},{"categories":[{"measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"39"},{"groupId":"BG003","value":"116"}]}],"title":"Not classifiable"}],"description":"ITT population. Stage of prostate cancer was classified according to the Tumour, Nodule and Metastatic classification that is a cancer staging system that describes the extent of cancer. T describes the size of the tumor and whether it has invaded nearby tissue, N describes regional lymph nodes that are involved, and M describes distant metastasis","paramType":"NUMBER","title":"Stage of Prostate Cancer","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"3.70","value":"26.6"},{"groupId":"BG001","spread":"4.21","value":"26.7"},{"groupId":"BG002","spread":"3.86","value":"26.9"},{"groupId":"BG003","spread":"3.93","value":"26.8"}]}]}],"description":"ITT population","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Body Mass Index","unitOfMeasure":"kilogram per square meter"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"8.2","upperLimit":"68","value":"19.9"},{"groupId":"BG001","lowerLimit":"9.4","upperLimit":"46","value":"19.8"},{"groupId":"BG002","lowerLimit":"8.7","upperLimit":"57","value":"19.0"},{"groupId":"BG003","lowerLimit":"8.7","upperLimit":"57","value":"19.0"}]}]}],"dispersionType":"INTER_QUARTILE_RANGE","paramType":"MEDIAN","title":"Serum Prostate-specific Antigen Levels","unitOfMeasure":"nanogram per milliliter"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"2.86","upperLimit":"5.05","value":"3.78"},{"groupId":"BG001","lowerLimit":"3.05","upperLimit":"5.32","value":"4.11"},{"groupId":"BG002","lowerLimit":"2.91","upperLimit":"5.01","value":"3.84"},{"groupId":"BG003","lowerLimit":"2.89","upperLimit":"5.10","value":"3.93"}]}]}],"dispersionType":"INTER_QUARTILE_RANGE","paramType":"MEDIAN","title":"Serum Testosterone Levels","unitOfMeasure":"nanogram per milliliter"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"1109","value":"485"},{"groupId":"BG001","spread":"994","value":"491"},{"groupId":"BG002","spread":"1088","value":"497"},{"groupId":"BG003","spread":"1063","value":"491"}]}]}],"description":"ITT population.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Time Since Prostate Cancer Diagnosis","unitOfMeasure":"days"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"13.0","value":"78.7"},{"groupId":"BG001","spread":"14.9","value":"79.8"},{"groupId":"BG002","spread":"12.2","value":"79.4"},{"groupId":"BG003","spread":"13.4","value":"79.3"}]}]}],"description":"ITT population","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Weight","unitOfMeasure":"kilogram"}]}